● AI Equity Research · Healthcare

COMPASS Pathways plc (CMPS)

AI stock analysis · Medical Care Facilities · Last analyzed Jul 8, 2026

Compass Score

3.0/5

Call

Hold

Price

$13.43

AI Target

$23.60 +75.8%

AI Analyst Summary

COMPASS Pathways is a clinical-stage psychedelic medicine company whose primary bull thesis rests on COMP360 (psilocybin therapy), currently in Phase 3 trials for treatment-resistant depression — a multi-billion dollar unmet need with no approved alternatives. A near-unanimous Strong Buy consensus among 15 analysts and a mean price target implying 75%+ upside reflects high conviction in the pipeline's transformative potential. The key risk is binary clinical-stage execution: any Phase 3 setback, regulatory rejection, or capital raise could materially impair the stock.

Catalysts

Phase 3 COMP360 trial readout for treatment-resistant depression — a positive data release would be the single largest re-rating event and could drive significant institutional inflows.
Regulatory milestone or FDA Breakthrough Therapy designation progress, which could accelerate the approval timeline and validate the commercial pathway for psilocybin therapy.
Potential partnership or licensing deal with a major pharmaceutical company, which would provide non-dilutive capital and validate the platform's commercial viability ahead of launch.

Risks

Binary Phase 3 trial risk: a failed or inconclusive COMP360 efficacy readout could erase the majority of market capitalization given the pipeline is concentrated in a single lead asset.
Dilution risk: as a cash-burning clinical-stage company with no revenue, COMPASS will likely require additional equity raises, potentially pressuring share price by 15–30% per offering.
Regulatory and scheduling uncertainty: psilocybin remains a Schedule I controlled substance in the US; DEA rescheduling delays or restrictive REMS requirements could significantly narrow the commercial opportunity even upon FDA approval.

Fundamentals

Pe N/A (loss-making) · 1.0/5

Company is pre-profitability with no trailing P/E available and a negative forward P/E of -12.4x, reflecting ongoing net losses typical of clinical-stage biopharma. No near-term path to GAAP earnings.

Peg N/A · 3.0/5

PEG ratio is unavailable given the company's pre-revenue, loss-making stage. Scored neutrally per guidelines; valuation must be assessed on pipeline milestones rather than earnings multiples.

Analyst Rating Strong Buy consensus (1.3) · 5.0/5

14 Buy ratings and 1 Hold among 15 covering analysts yields a consensus of 1.3 — firmly in Strong Buy territory. Broad analyst conviction with zero Sell ratings is a strong bullish signal.

Earnings Trend N/A (pre-revenue clinical stage) · 2.0/5

No earnings or revenue growth metrics are available; the company is in clinical development. Losses are expected but there is no visibility into a near-term inflection. Scored below average given the absence of positive earnings trajectory.

Price Target Beat 2 of 4 quarters beat · 2.0/5

EPS beat rate of 2 out of 4 recent quarters falls below expectations, suggesting inconsistent execution relative to analyst models. Limited history reduces confidence in this metric for a clinical-stage company.

Management Mixed · 3.0/5

Only 4 quarters of EPS history available with a 50% beat rate, indicating mixed execution. However, strong analyst coverage and near-unanimous Buy consensus suggest reasonable confidence in management's clinical and capital allocation strategy. Scored neutrally given limited operational track record.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.